Loading
Medical oncologist known for germ cell tumour research and anti-EGFR trials in colorectal cancer.
Carsten Bokemeyer is Director of the Department of Oncology, Hematology and BMT at Universitätsklinikum Hamburg-Eppendorf. A medical oncologist, his specialisms are testicular cancer, colorectal cancer and medical oncology. He led the OPUS trial of cetuximab with FOLFOX in colorectal cancer and has a long record in germ cell tumour research. His papers include a study of early tumour shrinkage as a predictor of long-term outcome in cetuximab-treated metastatic colorectal cancer, a European Urology report establishing serum microRNA miR-371a-3p as a biomarker for germ cell tumours, and a review of catumaxomab, a trifunctional anti-EpCAM antibody used for malignant ascites. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites | Expert Opinion on Biological Therapy | 2010 |
| Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours | European Urology | 2017 |
| Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab | Journal of Clinical Oncology | 2013 |
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.
Shares Cetuximab, Colorectal cancer.